Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) Director Arthur S. Kirsch acquired 50,000 shares of the company’s stock in a transaction on Wednesday, June 14th. The shares were acquired at an average cost of $1.17 per share, for a total transaction of $58,500.00. Following the completion of the acquisition, the director now owns 206,609 shares of the company’s stock, valued at $241,732.53. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Aralez Pharmaceuticals Inc. (ARLZ) opened at 1.34 on Tuesday. The firm’s 50-day moving average price is $1.33 and its 200-day moving average price is $2.82. The stock’s market cap is $88.23 million. Aralez Pharmaceuticals Inc. has a 12 month low of $1.09 and a 12 month high of $6.80.
Aralez Pharmaceuticals (NASDAQ:ARLZ) last issued its earnings results on Tuesday, May 9th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.40) by $0.02. The business had revenue of $26 million during the quarter, compared to the consensus estimate of $20.23 million. Aralez Pharmaceuticals had a negative return on equity of 66.74% and a negative net margin of 133.92%. The business’s revenue was up 221.0% on a year-over-year basis. During the same period in the prior year, the business earned ($0.73) EPS. On average, analysts predict that Aralez Pharmaceuticals Inc. will post ($1.56) earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This story was first posted by BBNS and is the property of of BBNS. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://baseballnewssource.com/markets/aralez-pharmaceuticals-inc-arlz-director-buys-58500-00-in-stock-updated-updated/1059926.html.
A number of analysts have recently weighed in on the company. ValuEngine lowered Aralez Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Chardan Capital reduced their price target on Aralez Pharmaceuticals from $10.00 to $5.50 and set a “buy” rating for the company in a report on Wednesday, March 15th. Finally, Bloom Burton raised Aralez Pharmaceuticals from an “accumulate” rating to a “buy” rating in a research report on Monday, April 10th.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Wsfs Capital Management LLC purchased a new position in Aralez Pharmaceuticals during the fourth quarter worth approximately $474,000. Broadfin Capital LLC raised its stake in Aralez Pharmaceuticals by 8.3% in the first quarter. Broadfin Capital LLC now owns 5,191,590 shares of the company’s stock valued at $11,110,000 after buying an additional 400,000 shares during the last quarter. Isthmus Partners LLC raised its stake in Aralez Pharmaceuticals by 4.9% in the first quarter. Isthmus Partners LLC now owns 153,102 shares of the company’s stock valued at $328,000 after buying an additional 7,110 shares during the last quarter. Norges Bank purchased a new position in shares of Aralez Pharmaceuticals during the fourth quarter valued at approximately $665,000. Finally, Dimensional Fund Advisors LP increased its position in shares of Aralez Pharmaceuticals by 2.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 314,224 shares of the company’s stock valued at $1,386,000 after buying an additional 7,014 shares during the period. Institutional investors and hedge funds own 35.64% of the company’s stock.
Aralez Pharmaceuticals Company Profile
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
Receive News & Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.